REGENERON PHARMACEUTICALS (RGO.DE) Fundamental Analysis & Valuation

FRA:RGO • US75886F1075

Current stock price

652 EUR
-6 (-0.91%)
Last:

This RGO.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. RGO.DE Profitability Analysis

1.1 Basic Checks

  • In the past year RGO was profitable.
  • RGO had a positive operating cash flow in the past year.
  • RGO had positive earnings in each of the past 5 years.
  • In the past 5 years RGO always reported a positive cash flow from operatings.
RGO.DE Yearly Net Income VS EBIT VS OCF VS FCFRGO.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

1.2 Ratios

  • RGO has a better Return On Assets (11.11%) than 87.50% of its industry peers.
  • Looking at the Return On Equity, with a value of 14.41%, RGO belongs to the top of the industry, outperforming 86.25% of the companies in the same industry.
  • RGO has a Return On Invested Capital of 7.54%. This is in the better half of the industry: RGO outperforms 80.00% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for RGO is below the industry average of 11.34%.
Industry RankSector Rank
ROA 11.11%
ROE 14.41%
ROIC 7.54%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)8.87%
ROIC(5y)14.2%
RGO.DE Yearly ROA, ROE, ROICRGO.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • Looking at the Profit Margin, with a value of 31.41%, RGO belongs to the top of the industry, outperforming 90.00% of the companies in the same industry.
  • In the last couple of years the Profit Margin of RGO has declined.
  • Looking at the Operating Margin, with a value of 27.02%, RGO belongs to the top of the industry, outperforming 82.50% of the companies in the same industry.
  • In the last couple of years the Operating Margin of RGO has declined.
  • RGO's Gross Margin of 86.56% is fine compared to the rest of the industry. RGO outperforms 77.50% of its industry peers.
  • RGO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.02%
PM (TTM) 31.41%
GM 86.56%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
RGO.DE Yearly Profit, Operating, Gross MarginsRGO.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. RGO.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so RGO is still creating some value.
  • The number of shares outstanding for RGO has been reduced compared to 1 year ago.
  • Compared to 5 years ago, RGO has less shares outstanding
  • The debt/assets ratio for RGO has been reduced compared to a year ago.
RGO.DE Yearly Shares OutstandingRGO.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
RGO.DE Yearly Total Debt VS Total AssetsRGO.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 7.42 indicates that RGO is not in any danger for bankruptcy at the moment.
  • RGO has a Altman-Z score of 7.42. This is amongst the best in the industry. RGO outperforms 81.25% of its industry peers.
  • The Debt to FCF ratio of RGO is 0.72, which is an excellent value as it means it would take RGO, only 0.72 years of fcf income to pay off all of its debts.
  • RGO's Debt to FCF ratio of 0.72 is amongst the best of the industry. RGO outperforms 92.50% of its industry peers.
  • RGO has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of RGO (0.09) is better than 67.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.72
Altman-Z 7.42
ROIC/WACC0.88
WACC8.55%
RGO.DE Yearly LT Debt VS Equity VS FCFRGO.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.3 Liquidity

  • A Current Ratio of 4.13 indicates that RGO has no problem at all paying its short term obligations.
  • RGO has a better Current ratio (4.13) than 81.25% of its industry peers.
  • A Quick Ratio of 3.56 indicates that RGO has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 3.56, RGO is doing good in the industry, outperforming 77.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.13
Quick Ratio 3.56
RGO.DE Yearly Current Assets VS Current LiabilitesRGO.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RGO.DE Growth Analysis

3.1 Past

  • RGO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.76%.
  • RGO shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.99% yearly.
  • Looking at the last year, RGO shows a small growth in Revenue. The Revenue has grown by 0.99% in the last year.
  • RGO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.04% yearly.
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%

3.2 Future

  • Based on estimates for the next years, RGO will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.96% on average per year.
  • The Revenue is expected to grow by 8.10% on average over the next years. This is quite good.
EPS Next Y5.35%
EPS Next 2Y11.15%
EPS Next 3Y11.8%
EPS Next 5Y10.96%
Revenue Next Year10.36%
Revenue Next 2Y10.21%
Revenue Next 3Y9.52%
Revenue Next 5Y8.1%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RGO.DE Yearly Revenue VS EstimatesRGO.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B 15B 20B
RGO.DE Yearly EPS VS EstimatesRGO.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20 40 60 80

More info and screens

Find the best growth stocksShow best growing peers

6

4. RGO.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 16.90, the valuation of RGO can be described as correct.
  • RGO's Price/Earnings ratio is rather cheap when compared to the industry. RGO is cheaper than 87.50% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.79, RGO is valued a bit cheaper.
  • Based on the Price/Forward Earnings ratio of 16.04, the valuation of RGO can be described as correct.
  • RGO's Price/Forward Earnings ratio is rather cheap when compared to the industry. RGO is cheaper than 90.00% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.80, RGO is valued a bit cheaper.
Industry RankSector Rank
PE 16.9
Fwd PE 16.04
RGO.DE Price Earnings VS Forward Price EarningsRGO.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, RGO is valued cheaper than 83.75% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of RGO indicates a rather cheap valuation: RGO is cheaper than 85.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 21.05
EV/EBITDA 11.8
RGO.DE Per share dataRGO.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • RGO has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.16
PEG (5Y)2.42
EPS Next 2Y11.15%
EPS Next 3Y11.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. RGO.DE Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.50%, RGO is not a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 0.60, RGO pays a better dividend. On top of this RGO pays more dividend than 93.75% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.91, RGO's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.5%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
RGO.DE Yearly Dividends per shareRGO.DE Yearly Dividends per shareYearly Dividends per share 2025 2026 0.2 0.4 0.6 0.8

5.3 Sustainability

  • 8.22% of the earnings are spent on dividend by RGO. This is a low number and sustainable payout ratio.
DP8.22%
EPS Next 2Y11.15%
EPS Next 3Y11.8%
RGO.DE Yearly Income VS Free CF VS DividendRGO.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B
RGO.DE Dividend Payout.RGO.DE Dividend Payout, showing the Payout Ratio.RGO.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

RGO.DE Fundamentals: All Metrics, Ratios and Statistics

REGENERON PHARMACEUTICALS

FRA:RGO (3/18/2026, 7:00:00 PM)

652

-6 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-30
Earnings (Next)04-27
Inst Owners90.78%
Inst Owner ChangeN/A
Ins Owners1.94%
Ins Owner ChangeN/A
Market Cap68.93B
Revenue(TTM)14.34B
Net Income(TTM)4.50B
Analysts81.11
Price Target740.12 (13.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0.5%
Yearly Dividend3
Dividend Growth(5Y)N/A
DP8.22%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.31%
Min EPS beat(2)5.66%
Max EPS beat(2)20.96%
EPS beat(4)3
Avg EPS beat(4)16.93%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)9.59%
EPS beat(12)10
Avg EPS beat(12)8.05%
EPS beat(16)13
Avg EPS beat(16)8.3%
Revenue beat(2)2
Avg Revenue beat(2)1.44%
Min Revenue beat(2)0.21%
Max Revenue beat(2)2.66%
Revenue beat(4)3
Avg Revenue beat(4)0.82%
Min Revenue beat(4)-9.32%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.06%
Revenue beat(12)8
Avg Revenue beat(12)0.91%
Revenue beat(16)12
Avg Revenue beat(16)1.57%
PT rev (1m)1.31%
PT rev (3m)7.77%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)-8.07%
EPS NY rev (1m)0.64%
EPS NY rev (3m)3.53%
Revenue NQ rev (1m)0.14%
Revenue NQ rev (3m)0.71%
Revenue NY rev (1m)1.17%
Revenue NY rev (3m)4.9%
Valuation
Industry RankSector Rank
PE 16.9
Fwd PE 16.04
P/S 5.53
P/FCF 21.05
P/OCF 15.92
P/B 2.54
P/tB 2.64
EV/EBITDA 11.8
EPS(TTM)38.59
EY5.92%
EPS(NY)40.65
Fwd EY6.24%
FCF(TTM)30.97
FCFY4.75%
OCF(TTM)40.95
OCFY6.28%
SpS117.97
BVpS257.09
TBVpS246.75
PEG (NY)3.16
PEG (5Y)2.42
Graham Number472.47
Profitability
Industry RankSector Rank
ROA 11.11%
ROE 14.41%
ROCE 10.71%
ROIC 7.54%
ROICexc 23.05%
ROICexgc 25.78%
OM 27.02%
PM (TTM) 31.41%
GM 86.56%
FCFM 26.25%
ROA(3y)11.58%
ROA(5y)16.27%
ROE(3y)14.89%
ROE(5y)21.37%
ROIC(3y)8.87%
ROIC(5y)14.2%
ROICexc(3y)17.08%
ROICexc(5y)22.5%
ROICexgc(3y)18.5%
ROICexgc(5y)23.56%
ROCE(3y)12.6%
ROCE(5y)20.17%
ROICexgc growth 3Y6.69%
ROICexgc growth 5Y2.24%
ROICexc growth 3Y4.54%
ROICexc growth 5Y-0.03%
OM growth 3Y-14.45%
OM growth 5Y-8.44%
PM growth 3Y-4.13%
PM growth 5Y-5.35%
GM growth 3Y-1.04%
GM growth 5Y-0.06%
F-Score5
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.72
Debt/EBITDA 0.61
Cap/Depr 223.23%
Cap/Sales 8.46%
Interest Coverage 93.15
Cash Conversion 112.68%
Profit Quality 83.58%
Current Ratio 4.13
Quick Ratio 3.56
Altman-Z 7.42
F-Score5
WACC8.55%
ROIC/WACC0.88
Cap/Depr(3y)208.61%
Cap/Depr(5y)258.46%
Cap/Sales(3y)7.24%
Cap/Sales(5y)7.69%
Profit Quality(3y)85.52%
Profit Quality(5y)83.15%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.76%
EPS 3Y1.53%
EPS 5Y6.99%
EPS Q2Q%-5.22%
EPS Next Y5.35%
EPS Next 2Y11.15%
EPS Next 3Y11.8%
EPS Next 5Y10.96%
Revenue 1Y (TTM)0.99%
Revenue growth 3Y5.62%
Revenue growth 5Y11.04%
Sales Q2Q%2.51%
Revenue Next Year10.36%
Revenue Next 2Y10.21%
Revenue Next 3Y9.52%
Revenue Next 5Y8.1%
EBIT growth 1Y-8.13%
EBIT growth 3Y-9.64%
EBIT growth 5Y1.67%
EBIT Next Year13.49%
EBIT Next 3Y14.31%
EBIT Next 5Y10.45%
FCF growth 1Y6.39%
FCF growth 3Y3.48%
FCF growth 5Y13.45%
OCF growth 1Y12.63%
OCF growth 3Y-0.24%
OCF growth 5Y13.72%

REGENERON PHARMACEUTICALS / RGO.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for REGENERON PHARMACEUTICALS?

ChartMill assigns a fundamental rating of 7 / 10 to RGO.DE.


Can you provide the valuation status for REGENERON PHARMACEUTICALS?

ChartMill assigns a valuation rating of 6 / 10 to REGENERON PHARMACEUTICALS (RGO.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for REGENERON PHARMACEUTICALS?

REGENERON PHARMACEUTICALS (RGO.DE) has a profitability rating of 7 / 10.


What are the PE and PB ratios of REGENERON PHARMACEUTICALS (RGO.DE) stock?

The Price/Earnings (PE) ratio for REGENERON PHARMACEUTICALS (RGO.DE) is 16.9 and the Price/Book (PB) ratio is 2.54.


Can you provide the dividend sustainability for RGO stock?

The dividend rating of REGENERON PHARMACEUTICALS (RGO.DE) is 3 / 10 and the dividend payout ratio is 8.22%.